Cybin Inc. (HELP) vs Rigel Pharmaceuticals, Inc. (RIGL)

Cybin Inc. and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Cybin Inc. and Rigel Pharmaceuticals, Inc. are of similar size ($926.4M and $894.6M). Cybin Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.7×. Rigel Pharmaceuticals, Inc. has the higher net margin (116.3% vs 0.00%) and the higher return on invested capital (16.5% vs −137.9%). Across the 13 metrics below, Rigel Pharmaceuticals, Inc. leads on 12 and Cybin Inc. on 1.

Valuation

Metric HELP RIGL Biotechnology median
P/E n/m 2.73 7.88
P/S n/m 3.23 11.47
P/B 2.73 2.10 2.52
Price to free cash flow n/m 99.48 21.16
EV/EBITDA n/m 9.16 0.74
EV/Sales n/m 2.94 10.73
Earnings yield (32.20%) 36.67% (28.84%)
Free cash flow yield (21.66%) 1.01% (23.03%)

Profitability

Metric HELP RIGL Biotechnology median
Gross margin 0.00% 91.39% 65.16%
Operating margin 0.00% 31.45% 0.00%
Net margin 0.00% 116.30% 0.00%
Free cash flow margin 0.00% 3.19% 0.00%
Return on equity (86.94%) 126.90% (57.72%)
Return on assets (72.78%) 88.46% (49.22%)
Return on invested capital (137.88%) 16.48% 0.00%

Growth

Metric HELP RIGL Biotechnology median
Revenue growth (TTM) — 3.31% 5.64%
EPS growth (last fiscal year) (5.72%) 1,867.68% —
Revenue growth, 5-year CAGR — 22.06% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric HELP RIGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.97 1.94 4.73
Net debt to EBITDA 1.10 (1.05) 0.96

Dividend

Metric HELP RIGL Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric HELP RIGL Biotechnology median
Market cap 926.40m 894.58m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack